Clinical Trials Logo

Filter by:
NCT ID: NCT01105936 Completed - Clinical trials for Osteoarthritis, Knee

Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)

Start date: September 2010
Phase: Phase 4
Study type: Interventional

Blood-Oxygen-Level-Dependent (BOLD) responses to painful mechanical stimulation of the OA knee following treatment with four consecutive doses (at 8 hour intervals) on giving sustained released paracetamol treatment or placebo will be compared. The fMRI and pain assessments will occur approximately 2-5 hours after taking the final dose.

NCT ID: NCT01104584 Completed - Breast Cancer Clinical Trials

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

GEMMA 2
Start date: May 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of the breasts) may benefit from MRI of the breasts as MRI may detect additional breast cancers

NCT ID: NCT01103323 Completed - Clinical trials for Metastatic Colorectal Cancer

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Start date: April 2010
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC

NCT ID: NCT01102608 Completed - Soft Tissue Sarcoma Clinical Trials

Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma

Start date: March 2008
Phase: Phase 2
Study type: Interventional

To study the activity and toxicity of a neoadjuvant regimen including high-dose ifosfamide in combination with radiotherapy, and subsequent surgery, in high-risk soft tissue sarcomas.

NCT ID: NCT01102595 Completed - Glioblastomas Clinical Trials

Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma

Start date: December 2009
Phase: Phase 2
Study type: Interventional

In the last 20 years, only temozolomide has obtained indication for the treatment of High-grade glioma (HGG). Temozolomide during and later radiation therapy has doubled one year survival and is the standard treatment for glioblastoma. But 30% of glioblastomas receive only a biopsy as they can't be resected and don't get benefit from this treatment. They and should be treated immediately after the biopsy to prevent neurological deterioration but in spite of this approach they often deteriorate neurologically during radiotherapy. . An effective pre-radiation treatment should improve their prognosis and allow them to complete concomitant radiotherapy and temozolomide treatment. Bevacizumab in recurrent HGG displays 63% of objective responses when combined with irinotecan. But irinotecan is not the most active treatment in this disease. We propose a phase II, two arms, open label, randomized, multicentric study with 2 cycles of temozolomide before radiation therapy and concomitant temozolomide, in patients with glioblastoma and 'biopsy-only'. Bevacizumab will be added to one arm.

NCT ID: NCT01102426 Completed - Clinical trials for Relapsed/Refractory Multiple Myeloma

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

ADMYRE
Start date: June 2010
Phase: Phase 3
Study type: Interventional

Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.

NCT ID: NCT01102283 Completed - Colonic Obstruction Clinical Trials

Treatment of Colonic Obstruction With Cook Evolution® Colonic Stent System

Start date: April 2010
Phase: N/A
Study type: Observational

The objective of this registry is to compile clinical data on the use of the Evolution® Colonic Stent System for the palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.

NCT ID: NCT01102127 Completed - Thyroid Cancer Clinical Trials

Elastography in Thyroid Nodules

Start date: February 2010
Phase: N/A
Study type: Observational

Nodular goiter is a highly prevalent disease in iodine-deficient areas. Usually nodule assessment includes ultrasonography (US) and fine-needle aspiration (FNA), but some benign nodules can hardly be distinguished from carcinomas. Elastography measures tissue elasticity using sonography, as malignancy is related to stiffness of solid organs. The investigators have designed a study to evaluate the diagnostic accuracy of elastography in nodular goiter. Consecutive patients will be assessed using US, FNA and elastography; the latter will be compared with cytology. Specificity, sensitivity, and predictive values will be calculated.

NCT ID: NCT01101009 Completed - Hypertension Clinical Trials

Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

Start date: April 2010
Phase: Phase 4
Study type: Interventional

Comparison of the combination of amlodipine with an angiotensin receptor blocker or an angiotensin converting inhibitor, on central arterial blood pressure in patients with hypertension and additional risk factors. This is a randomised, double-blind, double-dummy, multicenter study. The duration of active treatment 24 weeks.

NCT ID: NCT01100502 Completed - Disease, Hodgkin Clinical Trials

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Start date: April 30, 2010
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).